Zydus Cadila gets USFDA nod to market generic drug to treat headache
The drug will be manufactured at Nesher Pharma's manufacturing facility at St. Louis in the US, the drug firm says
 "Zydus Cadila gets USFDA nod to market generic drug to treat headache")
premium
Drug firm Zydus Cadila on Saturday said it has received final approval from the US health regulator to market generic Butalbital, Acetaminophen and Caffeine combination tablets to treat symptoms of tension headaches.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Butalbital, Acetaminophen and Caffeine tabletsin strengths of 50mg/325mg/40 mg, Zydus Cadila said in a statement.
The drug will be manufactured at Nesher Pharma's manufacturing facility at St. Louis in the US, it added.
This combination medication is used to treat symptom complex of tension (or muscle contraction) headaches, Zydus Cadila said.
Thegroup now has 294 approvals and has filed over 390 abbreviated new drug applications (ANDAs) since the commencement of the filing process, it added.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%